TG Therapeutics

TG Therapeutics is a single-product specialty-biotech focused on B-cell-mediated diseases, built around BRIUMVI (ublituximab), the third anti-CD20 monoclonal antibody approved for relapsing multiple sclerosis (RMS). FY2025 revenue USD 700 M (+69.6% growth), GAAP profit margin 65.95% (boosted by tax-benefit recognition; underlying operating margin 17%), EPS USD 2.86 — finally profitable after a decade of clinical and commercial investments. The 2022 FDA rejection of the ublituximab+umbralisib (U2) combination for CLL/SLL nearly bankrupted the company and forced CEO Michael Weiss to pivot the business entirely to MS — a transition that has now produced one of the strongest specialty-pharma launches of 2023-2025.

The 2026 strategic story has two threads. First, the BRIUMVI launch trajectory: the differentiated 1-hour twice-yearly infusion (versus Roche Ocrevus 3-4 hours and Novartis Kesimpta monthly self-injection) has captured share faster than analyst models, reaching 18% of new RMS patient starts at end-2025. BRIUMVI net product revenue ran USD 156 M in Q4/2025 (annualised USD 620 M+). Second, the subcutaneous formulation launch: BRIUMVI subcut is expected to launch in H2/2026 — a transformational format change because it converts the in-clinic IV burden to physician-office self-administration. This is a direct competitive response to Roche's Ocrevus Zunovo subcut launched 2024 and removes the last clinical-administration disadvantage versus self-injectable Kesimpta.

The 2026 question is whether the BRIUMVI launch continues at 18%+ new-start share through 2026, whether the subcut launch in H2/2026 accelerates capture, and whether TG Therapeutics can extend the franchise beyond RMS into other B-cell autoimmune indications (CNS lymphoma, progressive MS forms, autoimmune CNS conditions).

Top holders Q1/2026: Vanguard 7.8%, BlackRock 7.1%, Michael Weiss (CEO and Chairman) plus management approximately 5.5%, Renaissance Technologies 4.2%, Capital Group 3.6%, State Street 3.2%, Janus Henderson 2.1%. Free-float effectively 80%.

Most interesting move: Renaissance Technologies opened a fresh 4.2% position in Q4/2025 — quantitative-fund accumulation in a stock with 25.5% short interest is a classic signature of crowded-short fading. Janus Henderson added 38% to its position in Q1/2026 — first major US growth-fund accumulation since the 2022 U2-rejection bottom. Polar Capital trimmed 22% in Q1/2026 — a notable European-specialist-biotech reduction at sub-USD 40 prices.

Insider activity: CEO Michael Weiss (founder-CEO since 2010, survived the 2022 U2-collapse) bought USD 800k of stock in October 2025 at USD 32 — first major insider buy since 2022. CFO Sean Power exercised options in Q4/2025 and held 75% of resulting shares. President Adam Waldman (commercial lead for BRIUMVI) bought USD 200k in Q1/2026. Notably, no insider sells in 2024-2025 — a sustained discipline period after the executives sold at peak in 2021-2022.

Short interest 25.5% (short ratio 14.9 days to cover) — extreme. The bear thesis is concentrated on competitive intensity from Roche Ocrevus Zunovo subcut (launched 2024 with strong physician adoption), Novartis Kesimpta self-injection ease-of-use advantage, the single-product nature of TG Therapeutics, and the modest near-term pipeline beyond BRIUMVI. Any positive Q2-Q3/2026 launch update or subcut approval would trigger meaningful short-squeeze momentum.

P/E 13.8x distorted by tax-benefit recognition; normalised P/E 25-28x. Forward P/E 14.5x. P/S 8.6x, EV/EBITDA 40.3x. The right framework is risk-adjusted BRIUMVI peak-sales NPV. Peak BRIUMVI revenue USD 1.5-2.0 bn globally at 25-30% operating margin produces USD 375-600 M operating profit annual. NPV at 8% discount with 10-year visibility is approximately USD 4-6 bn — broadly in line with current enterprise value USD 6.0 bn. Sell-side PT consensus USD 48.00 (range USD 17-70): JP Morgan most bullish at USD 70 (subcut launch accelerates + BRIUMVI peaks above USD 2 bn + label expansion succeeds), Morgan Stanley most bearish at USD 17 (Ocrevus Zunovo subcut takes share + competitive pricing pressure). 7 analysts cover, recommendation buy. Implied probability of strong subcut launch + share-capture continuation in current price approximately 50%. Bull case USD 65 (+65%) on subcut H2/2026 strong + BRIUMVI 25% new-start share + label expansion. Bear case USD 22 (-44%) on Ocrevus Zunovo dominates new starts + BRIUMVI peaks at USD 1 bn.

1. Q2 2026: Q1/2026 results — BRIUMVI net product revenue trajectory + subcut PDUFA date confirmation
2. H2 2026: BRIUMVI subcutaneous FDA approval + launch — operational differentiation restoration
3. Q1 2027: Subcut early-launch metrics — conversion rate from IV + new-start capture rate

TG Therapeutics is the rare commercial-stage specialty-biotech that has actually achieved the launch-to-profitability inflection. BRIUMVI is taking RMS share faster than analyst models — and the subcut launch is the critical catalyst that determines whether the franchise compounds to USD 2 bn peak or plateaus at USD 1 bn. The 25.5% short interest is a contrarian bull signal — bears are crowded into a single-product company at the moment its most important format launch is about to happen. The bear case is real: Ocrevus Zunovo subcut is a meaningful competitor and Kesimpta self-injection has structural ease-of-use advantage. I size TGTX at 1-1.5% as a specialty-biotech satellite with launch-momentum exposure. The trade I would not make is sizing above 2.5% — single-product biotech risk is non-zero, especially given the 2022 U2 history. Add trigger: BRIUMVI subcut FDA approval + Q3/2026 net product revenue above USD 200 M quarterly. Cut trigger: any commercial setback in 2026 BRIUMVI launch trajectory or unexpected pipeline disappointment. This is a launch-momentum specialty trade, not a hold-forever name — when subcut conversion peaks in 2027-2028, take profit before competitive pressures dominate.